Firm Represents Circle Pharma in $45 Million Series B Financing

On March 17, 2020, Circle Pharma, Inc., a macrocycle drug discovery and development company focused on intractable cancer targets, announced that it has raised $45 million in a Series B financing. Wilson Sonsini Goodrich & Rosati represented Circle Pharma in the transaction.

The financing was led by The Column Group, with participation by Nextech Invest. All investors from the prior round–ShangPharma, LifeForce Capital, and the Berkeley Catalyst Fund–joined the financing. Proceeds from the investment will be used to advance Circle’s work to develop inhibitors of Cyclin A and Cyclin E, and to expand the company’s pipeline.

The Wilson Sonsini team representing Circle Pharma in the transaction includes Elton Satusky, Jesse Schumaker, Kathy Jordan, and Theo Haboucha.

For more information, please see Circle Pharma's press release.